Compumedics (ASX:CMP) Common Stock : A$35.65 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Compumedics Common Stock?

Compumedics's quarterly common stock stayed the same from Dec. 2022 (A$35.65 Mil) to Jun. 2023 (A$35.65 Mil) and stayed the same from Jun. 2023 (A$35.65 Mil) to Dec. 2023 (A$35.65 Mil).

Compumedics's annual common stock stayed the same from Jun. 2021 (A$35.65 Mil) to Jun. 2022 (A$35.65 Mil) and stayed the same from Jun. 2022 (A$35.65 Mil) to Jun. 2023 (A$35.65 Mil).

Compumedics Common Stock Historical Data

The historical data trend for Compumedics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compumedics Common Stock Chart

Compumedics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Common Stock

Get a 7-Day Free Trial

35.65

Compumedics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Common Stock	Get a 7-Day Free Trial															35.65	35.65	35.65	35.65	35.65

Compumedics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Compumedics (ASX:CMP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Compumedics Ltd (ASX:CMP) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

30-40 Flockhart Street, Abbotsford, Melbourne, VIC, AUS, 3067

Website

https://www.compumedics.com.au

Compumedics Ltd is a medical device company. It is engaged in the development, manufacture, and commercialisation of diagnostic technologies for sleep, brain and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of Americas, Australia and the Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.